Like many more, Enzo Biochem (NYSE:ENZ) reveals its operations are negatively affected by COVID-19 disruptions( such as a material decrease in lab testing amounts, including that the pandemic’s impacts on its own worldwide distribution chain could hamper creation inside its own life sciences unit in addition to testing capabilities within its clinical laboratory. It might also experience problems collecting payments from clients.
COVID-19 services and products should partly offset revenue declines.
In the end of Marchit had $48M cash and no long term debt. As a result of high amount of uncertainty linked to the length and consequences of this contagion, it’s not able to gauge the effect on its operations moving forward.